Mink Therapeutics Stock Beta
| INKT Stock | USD 0.68 0.01 1.45% |
Mink Therapeutics fundamentals help investors to digest information that contributes to Mink Therapeutics' financial success or failures. It also enables traders to predict the movement of Mink Stock. The fundamental analysis module provides a way to measure Mink Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mink Therapeutics stock.
Mink | Beta |
Mink Therapeutics Company Beta Analysis
Mink Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Mink Therapeutics Beta | 0.048 |
Most of Mink Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mink Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Mink Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Mink Therapeutics is extremely important. It helps to project a fair market value of Mink Stock properly, considering its historical fundamentals such as Beta. Since Mink Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Mink Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Mink Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Mink Therapeutics has a Beta of 0.048. This is 94.42% lower than that of the Biotechnology sector and 96.55% lower than that of the Health Care industry. The beta for all United States stocks is 132.0% lower than that of the firm.
Mink Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mink Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mink Therapeutics could also be used in its relative valuation, which is a method of valuing Mink Therapeutics by comparing valuation metrics of similar companies.Mink Therapeutics is currently under evaluation in beta category among its peers.
Mink Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Mink Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Mink Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Mink Therapeutics' value.| Shares | Wells Fargo & Co | 2024-06-30 | 10.9 K | Greenwich Wealth Management Llc | 2024-09-30 | 10.8 K | Tower Research Capital Llc | 2024-06-30 | 8.9 K | Ubs Group Ag | 2024-06-30 | 3.2 K | Bank Of America Corp | 2024-06-30 | 2 K | Qube Research & Technologies | 2024-06-30 | 1.9 K | California State Teachers Retirement Sys | 2024-06-30 | 1.5 K | Advisor Group Holdings, Inc. | 2024-06-30 | 1.4 K | Covestor Ltd | 2024-06-30 | 1.1 K | Vanguard Group Inc | 2024-09-30 | 234.2 K | Longbow Finance Sa | 2024-09-30 | 166.7 K |
As returns on the market increase, Mink Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Mink Therapeutics is expected to be smaller as well.
Mink Fundamentals
| Return On Equity | -12.39 | ||||
| Return On Asset | -0.97 | ||||
| Current Valuation | 25.18 M | ||||
| Shares Outstanding | 39.55 M | ||||
| Shares Owned By Insiders | 74.64 % | ||||
| Shares Owned By Institutions | 2.25 % | ||||
| Number Of Shares Shorted | 51.73 K | ||||
| Price To Book | 10.05 X | ||||
| EBITDA | (22.25 M) | ||||
| Net Income | (22.46 M) | ||||
| Cash And Equivalents | 29.85 M | ||||
| Cash Per Share | 0.88 X | ||||
| Total Debt | 22.61 M | ||||
| Current Ratio | 1.74 X | ||||
| Book Value Per Share | (0.52) X | ||||
| Cash Flow From Operations | (15.76 M) | ||||
| Short Ratio | 1.10 X | ||||
| Earnings Per Share | (0.37) X | ||||
| Target Price | 6.67 | ||||
| Number Of Employees | 31 | ||||
| Beta | 0.048 | ||||
| Market Capitalization | 26.89 M | ||||
| Total Asset | 4.55 M | ||||
| Retained Earnings | (133.4 M) | ||||
| Working Capital | (7.8 M) | ||||
| Net Asset | 4.55 M |
About Mink Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mink Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mink Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mink Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mink Stock Analysis
When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.